The Computational Future and Biomedicine (Video Available)

Speaker: Stephen Wolfram, PhD, at Wolfram Research

Date: October 7, 2021 at 4:00PM - 5:30PM

Dr. Stephen Wolfram  –  creator of Mathematica, Wolfram|Alpha and the Wolfram Language; the author of A New Kind of Science; the originator of the Wolfram Physics Project; and the founder and CEO of Wolfram Research – will speak about the computational future and biomedicine. Dr. Wolfram will share a roadmap for recentering biomedicine around computation and give insights into harnessing data driven science to transform the biomedical landscape. This should be a relevant and an illuminating talk from one of the foremost leaders in computational health.  

Stephen Wolfram is the creator of MathematicaWolfram|Alpha and the Wolfram Language; the author of A New Kind of Science; the originator of the Wolfram Physics Project; and the founder and CEO of Wolfram Research. Over the course of more than four decades, he has been a pioneer in the development and application of computational thinking—and has been responsible for many discoveries, inventions and innovations in science, technology and business. Born in London in 1959, Wolfram was educated at EtonOxford and Caltech. He published his first scientific paper at the age of 15, and had received his PhD in theoretical physics from Caltech by the age of 20. Wolfram's early scientific work was mainly in high-energy physicsquantum field theory and cosmology, and included several now-classic results. Having started to use computers in 1973, Wolfram rapidly became a leader in the emerging field of scientific computing, and in 1979 he began the construction of SMP—the first modern computer algebra system—which he released commercially in 1981. In recognition of his early work in physics and computing, Wolfram became in 1981 the youngest recipient of a MacArthur Fellowship. Late in 1981 Wolfram then set out on an ambitious new direction in science aimed at understanding the origins of complexity in nature. Wolfram's first key idea was to use computer experiments to study the behavior of simple computer programs known as cellular automata. And starting in 1982, this allowed him to make a series of startling discoveries about the origins of complexity. The papers Wolfram published quickly had a major impact, and laid the groundwork for the emerging field that Wolfram called complex systems research.


Publications

Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD, Kinsella JP, Mandl KD, Raj JU, Sleeper LA, . Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. The Journal of pediatrics 2022.

Wang X, Zhang HG, Xiong X, Hong C, Weber GM, Brat GA, Bonzel CL, Luo Y, Duan R, Palmer NP, Hutch MR, Gutiérrez-Sacristán A, Bellazzi R, Chiovato L, Cho K, Dagliati A, Estiri H, García-Barrio N, Griffier R, Hanauer DA, Ho YL, Holmes JH, Keller MS, Klann MEng JG, L'Yi S, Lozano-Zahonero S, Maidlow SE, Makoudjou A, Malovini A, Moal B, Moore JH, Morris M, Mowery DL, Murphy SN, Neuraz A, Yuan Ngiam K, Omenn GS, Patel LP, Pedrera-Jiménez M, Prunotto A, Jebathilagam Samayamuthu M, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano-Balazote P, South AM, Tan ALM, Tan BWL, Tibollo V, Tippmann P, Visweswaran S, Xia Z, Yuan W, Zöller D, Kohane IS, Avillach P, Guo Z, Cai T, . SurvMaximin: Robust federated approach to transporting survival risk prediction models. Journal of biomedical informatics 2022.

Torous J, Stern AD, Bourgeois FT. Regulatory considerations to keep pace with innovation in digital health products. NPJ digital medicine 2022.

Levy S, Wisk LE, Minegishi M, Ertman B, Lunstead J, Brogna M, Weitzman ER. Association of Screening and Brief Intervention With Substance Use in Massachusetts Middle and High Schools. JAMA network open 2022.

Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Co-existing alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer immunology research 2022.